Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Trinity Biotech plc To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Trinity Biotech plc (“Trinity” or the “Company”) (NasdaqGS:TRIB).
The investigation focuses on whether the Company and its executives violated federal securities laws by potentially misrepresenting the likelihood of the marketing applications of its point-of-care testing devices to be accepted by the Food and Drug Administration (“FDA”).
Specifically, on October 4, 2016, the Company announced that it would withdraw its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the advice of the FDA. The Company also announced that it would close down its Swedish facility, eliminating 40 jobs and generating $50 million in redundancy and closure costs, and that it would reduce expenditure levels from $9 million to $1.5 million per annum.
After this announcement, Trinity’s share price fell from $12.99 per share on October 3, 2016 to a closing price of $6.46 on October 4, 2016—a $6.53 or a 50.3% drop.
If you invested in Trinity stock or options and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Trinity’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.
* The submission of this form does not create an attorney-client relationship.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.